Celldex Therapeutics(NASDAQ) CLDX

Celldex Therapeutics develops medicines for severe allergy and skin problems. These treatments stop immune cells from causing itching and painful swelling. The company helps patients who lack relief from standard drugs.

Fighting Inflammation With Antibodies

• Barzolvolimab: Monoclonal antibody designed to block the KIT receptor and reduce mast cell activity in autoimmune diseases.
• CDX-622: Bispecific antibody targeting two inflammatory pathways to treat asthma and allergies; currently in phase 1 trials.
• Next-Generation Platform: Technology used to develop antibodies that can target multiple disease pathways simultaneously.

Advancing the Pipeline

• Initiated two phase 3 studies for barzolvolimab in chronic hives during July 2024.
• Commenced a phase 3 trial for cold-induced hives and skin sensitivity in December 2025.
• Completed a $323.8 million underwritten public offering of common stock in April 2026.
• Expanded laboratory and office space in Hampton, New Jersey, during June 2026.

Targeting the Source of Disease

Celldex focuses on depleting mast cells to treat the underlying causes of inflammatory disorders rather than just managing symptoms. Its approach utilizes monoclonal and bispecific antibodies to engage the immune system and inhibit specific disease pathways.

Tracking the Research Spend

• Cash, cash equivalents, and marketable securities reached $717.6 million as of June 30, 2026.
• Net loss was $152.2 million for the six-month period ended June 30, 2026, up 38% year over year.
• Research and development expenses were $140.5 million for the first half of 2026, up 32% year over year.
• Total revenue was $37,000 for the six-month period ended June 30, 2026, down 97% year over year.
• Net proceeds from an April 2026 stock offering provided $323.8 million to support clinical development.

Evolution and Strategic Focus

Celldex has evolved into a late-stage clinical developer focusing on high-need inflammatory and autoimmune conditions. The advancement of its lead candidate into phase 3 trials and successful capital raises provide the foundation for potential commercial operations.